SCHEMBL285270

SCHEMBL285270

CCCC(C)C(O)C=S

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11770298 0.75
SCHEMBL14943049 0.75
SCHEMBL13176852 0.75
SCHEMBL1055155 0.75
SCHEMBL7093328 0.73 LMNA (0.38)
SCHEMBL11140379 0.73
SCHEMBL650364 0.70
SCHEMBL276772 0.70 METAP1 (0.31)
SCHEMBL15188474 0.69
SCHEMBL10927344 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10925885-B2 Thyromimetics for the treatment of fatty liver diseases METABASIS THERAPEUTICS, INC. (US) 2021-02-23 US disclosed
US-10807946-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2020-10-20 US disclosed
US-20190218176-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2019-07-18 US disclosed
US-10307434-B2 Nucleic acid prodrugs and methods of use thereof WAVE LIFE SCIENCES LTD. (SG) 2019-06-04 US disclosed
US-10239829-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2019-03-26 US disclosed
US-20190083515-A1 THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2019-03-21 US disclosed
US-10174062-B2 Activators of glucokinase METABASIS THERAPEUTICS, INC. (US) 2019-01-08 US disclosed
EP-2786985-B1 Antagonists of the glucagon receptor METABASIS THERAPEUTICS INC (US) 2018-11-28 EP disclosed
US-10130643-B2 Thyromimetics for the treatment of fatty liver diseases METABASIS THERAPEUTICS, INC. (US) 2018-11-20 US disclosed
US-10005805-B2 2018-06-26 US disclosed
WO-2006128055-A2 NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS METABASIS THERAPEUTICS, INC. (US) 2006-11-30 WO disclosed
WO-2006128058-A2 THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES METABASIS THERAPEUTICS, INC. (US) 2006-11-30 WO disclosed
WO-2006128056-A2 NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS METABASIS THERAPEUTICS, INC. (US) 2006-11-30 WO disclosed
EP-1689383-A2 NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS Metabasis Therapeutics, Inc. (US) 2006-08-16 EP disclosed
US-7045309-B2 Inhibit adenylyl cyclase in cells but have little effect on isolated adenylyl cyclase; useful as prodrugs for inhibiting adenylyl cyclase and lowering 3':5'-cAMP in cells, thereby inhibiting adenylyl cyclase dependent effects within cells THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2006-05-16 US disclosed
US-20060046980-A1 Novel phosphorus-containing thyromimetics METABASIS THERAPEUTICS, INC. 2006-03-02 US disclosed
WO-2006023515-A2 NOVEL THIAZOLE INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE METABASIS THERAPEUTICS, INC. (US) 2006-03-02 WO disclosed
WO-2005051298-A2 NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS METABASIS THERAPEUTICS, INC. (US) 2005-06-09 WO disclosed
US-20040053825-A1 9-Substituted adenine derivatives as prodrug regulators of cell and tissue function THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK 2004-03-18 US disclosed
WO-2002004475-A1 9-SUBSTITUTED ADENINE DERIVATIVES AS PRODRUG REGULATORS OF CELL AND TISSUE FUNCTION THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2002-01-17 WO disclosed